EarningsQ2 2026 Earnings Report
MX:OPCH Q2 2026 EPS Results
Actual EPS$7.75
Consensus EPS$7.34
Beat/MissBeat by +$0.41
One Year Ago EPS$7.06
MX:OPCH Q2 2026 Revenue Results
Actual Revenue$24.85B
Expected Revenue$24.46B
Beat/MissBeat by +$392.06M
YoY Revenue Growth+1.86%
Earnings Announcement Details
QuarterQ2 2026
Date07/29/2026
TimeBefore Open
Conference CallWednesday, July 29, 2026
MX:OPCH Upcoming Earnings
Option Care Health's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:OPCH Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balance of meaningful operational and financial positives — including sequential revenue and EBITDA growth, strong cash generation ($184M in Q2), active share repurchases ($150M), clinic expansion, and progress in key portfolios (acute, IG neuro, rare/orphan) — while acknowledging persistent headwinds tied to the CID portfolio that are expected to depress 2026 revenue (~600 bps) and gross profit (~$55M). Management emphasized execution of commercial, technology and cost initiatives to drive sequential improvement through the back half of the year, but several initiatives and new therapy launches carry timing and execution risk.Company Guidance
Revenue Growth (Q2 2026)
Reported revenue of $1.4 billion, up 2% year-over-year and up 7% sequentially from Q1 2026.
Adjusted EBITDA and EPS Improvement
Adjusted EBITDA of $117.5 million, up 3% year-over-year and up 12% sequentially; adjusted EPS of $0.45, a $0.04 increase versus last year (with ~ $0.03 uplift from share repurchases).
Strong Cash Generation and Balance Sheet
Operating cash flow of $184 million in Q2 2026; maintained full-year operating cash flow target of at least $320 million; net debt leverage ratio of 2.1x at quarter end.
Share Repurchase Activity
Repurchased $150 million of stock in Q2 (nearly 5% of shares outstanding); remaining buyback authorization of $525 million; no additional buybacks embedded in current guidance.
Acute Therapy Performance
Acute therapy portfolio delivered high-single-digit organic growth, above market, with sequential and year-over-year growth across key therapeutic categories and patient counts.
Strength in IG Neuro and Rare/Orphan Portfolios
IG neuro portfolio showed sequential and year-over-year revenue growth; rare and orphan portfolio delivered solid sequential and year-over-year growth and new therapies were added to the pipeline (some launching late 2026/early 2027).
Clinic Expansion and Utilization
Added 5 new ambulatory infusion clinics in Q2; clinic visits grew more than 20% year-over-year; over 35% of nursing visits conducted in infusion suites or clinics during the quarter.
SG&A and Expense Control
SG&A decreased 3% year-over-year to ~11% of revenue, driven by lower indirect labor and expense control initiatives (including reduction in variable compensation) while continuing investment in commercial resources.
Maintained Full-Year Guidance and Narrowed Ranges
Full-year revenue guidance unchanged at $5.675B–$5.775B; adjusted EBITDA narrowed to $480M–$495M; adjusted EPS narrowed to $1.85–$1.92; Q3 modeled as low-to-mid single-digit sequential revenue growth and mid-single-digit sequential EBITDA growth.
Technology and AI Investments
Ongoing investments in AI, digital tools, workflow automation and advanced analytics aimed at improving care coordination, nurse productivity, claims/authorization processes and reducing administrative costs; deployments underway in test markets and rolling out more broadly.
MX:OPCH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed